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baseline costs, while switchers to an SNRI had a $254 reduction. However, switchers 
to a generic SSRI had a $99 increase in medical costs. Controlling for baseline char-
acteristics, escitalopram switchers had the highest total health care cost reduction of 
the three groups, with $383 (P  0.016) in savings relative to SNRI switchers and
$172 (P  0.276) in savings relative to switchers to a generic SSRI. CONCLUSIONS:
MDD patients requiring second line therapy who switched to escitalopram had sig-
niﬁ cantly lower urgent care utilization than patients switching to an SNRI or another 
generic SSRI. Using escitalopram as second-line therapy appears to be a cost saving
strategy compared to using SNRIs or generic SSRIs.
PMH20
RETROSPECTIVE COHORT STUDY OF THE EFFECTS OF EARLY
VERSUS LATE TREATMENT OF INSOMNIA IN PATIENTS INITIATING
ANTI-DEPRESSANT MEDICATIONS
Delea T1, Hagiwara M1, Mallya U2
1Policy Analysis Inc. (PAI), Brookline, MA, USA, 2Novartis Pharmaceuticals Corporation, 
East Hanover, NJ, USA
OBJECTIVES: Antidepressants may alleviate insomnia in depressed patients. The
effects of antidepressants may be delayed, however, with potentially adverse effects
on compliance and persistence, health care costs, and work loss. We sought to assess
whether early treatment of insomnia improves outcomes and reduces costs in patients 
initiating antidepressants. METHODS: Retrospective cohort study of persons initiat-
ing anti-insomnia medications a1 year after initiating antidepressants in health-
insurance claims database (50 million members covered by large US employers, 
years 2002–2006). Patients initiating anti-insomnia medications a3 weeks after 
initiation of antidepressants (“early treatment”) were matched to patients initiating 
anti-insomnia medications 3–52 weeks after initiation of antidepressants (“late treat-
ment”) based on propensity scores and other baseline characteristics and compared
in terms of compliance, therapy switching, health care utilization and costs, and
days and employer costs of paid absences during 1 year follow-up. RESULTS: Early
and late-treated patients (n  4976 pairs) were well matched on baseline characteristics
including age (both 44 years, p  .5696), sex (34% and 35%, p  .3523), class of 
initial anti-depressant (SSRIs 77% for both), comorbidities, and pre-index health
care utilization and costs. Compared with those receiving late treatment with anti-
insomnia medications, those receiving early treatment were less likely to switch
antidepressants (30% vs. 40%, p  .0001), had fewer physicians ofﬁ ce visits (mean
[SD] 8.5 [9.7] vs. 9.9 [10.2], p  .0001), were less likely to have hospitalizations/
emergency department visits (34% vs. 39%, p  .0001), and had lower health care
costs during follow-up (mean [SD] $9,152 [$24,769] vs. $10,587 [$22,078], p 
0.0020). Among patients with paid absence data (n  56 pairs), early treated patients
had fewer paid absence hours (mean [SD] 153 [107] vs. 254 [317], p  0.0322) and 
lower employer paid absence costs (mean [SD] $3780 [$2669] vs. $6296 [$7893], p
 0.0328). CONCLUSIONS: Early and appropriate treatment for insomnia may
reduce frequency of switching of antidepressant therapy and lower health care and
employer costs.
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OBJECTIVES: This study examines, from a U.S. health care perspective, the cost-
effectiveness of olanzapine long-acting injection (OLAI) compared to risperidone
long-acting injection, haloperidol decanoate, and oral olanzapine in the treatment of 
schizophrenia patients who are nonadherent with oral antipsychotics. METHODS: A
1-year microsimulation economic decision model was developed to simulate the 
dynamic usual care of schizophrenia patients who may switch, continue, discontinue, 
and restart medications. The model captures clinical and cost parameters including
adherence levels, relapse with and without hospitalization, quality adjusted life years 
(QALYs), treatment discontinuation by reason, treatment-emergent adverse events, 
suicide, health care resource utilization, and direct medical care costs. Published 
medical literature, unpublished data, and a clinical expert panel were used to develop
baseline model assumptions. Key model outcomes included annual total direct cost 
per treatment, cost per stable patient, and incremental cost-effectiveness values per 1
QALY gained. RESULTS: OLAI was found to have an incremental cost of $60,273/
QALY over haloperidol decanoate. OLAI dominated all other comparators by produc-
ing more QALYs and fewer inpatient relapses (dominant over RLAI) or by producing 
more QALYs and fewer inpatient relapses with a lower incremental cost-effectiveness 
ratio (extended dominance over oral olanzapine). The base case and multiple sensitiv-
ity analyses found OLAI to be a cost-effective option in terms of incremental cost/
QALY gained. Results were most sensitive to change in the cost of relapse. CONCLU-
SIONS: OLAI is projected in this microsimulation model to be a cost-effective treat-
ment option for a costly, complex, and challenging group of patients – nonadherent 
schizophrenia patients – by yielding more QALYs and fewer inpatient relapses than
each comparator and providing a cost-effective option in terms of incremental cost 
per QALY gained.
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OBJECTIVES: Agomelatine is the ﬁ rst melatonergic antidepressant approved by the 
European Medicine Agency for the treatment of major depressive disorder (MDD) in 
adults. The objective of our study was to perform a cost-effectiveness analysis for
agomelatine based on clinical trials against placebo and venlafaxine from a Swedish 
societal perspective. METHODS: We developed a Markov model with health states
for well, depressive episode, remission and death. The model also incorporated sleep 
disorders, discontinuation rates, discontinuation symptoms and adverse drug reactions 
(incl. constipation, diarrhoea, dyspepsia, headache, nausea, somnolence and sexual
dysfunction). The time horizon was set to two years. Relapse and discontinuation rates
were estimated using Weibull regressions, while remission rates were estimated
directly. Costs and utilities for different health states were taken from a Swedish 
observational study. Frequencies of adverse events, sleep disorders and discontinuation
symptoms were taken from three relevant trials, while costs and disutilities were esti-
mated from the literature. Costs (reported in EUR 2008) and effects were discounted 
at 3% per year. RESULTS: In the base case, agomelatine is cost-saving and more 
effective than venlafaxine and placebo. One-way sensitivity analyses showed that the 
results were robust to most parameter changes. At a willingness-to-pay threshold of 
€50,000 per quality-adjusted life year gained, agomelatine was cost-effective compared 
to venlafaxine in 96% of the cases in the probabilistic sensitivity analysis. CONCLU-
SIONS: Based on data from clinical trials and the literature, our results indicate that 
agomelatine is cost-saving and more effective than venlafaxine in treating MDD in 
Sweden. These results are robust, conﬁ rmed by sensitivity analysis.
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OBJECTIVES: Of the various subtypes of anxiety disorders, generalized anxiety dis-
order (GAD) is the most frequent, lifetime prevalence 6.2%, and is connected with
relevant economic and societal consequences. The aim of this study was to assess the 
cost-effectiveness of pregabalin in the treatment of GAD from an institutional perspec-
tive. METHODS: We developed a three-state Markov model to simulate health and 
economic outcomes during a time horizon of one-year (12-week cycles). The model 
includes several stages related to disability (complete response, partial response and 
relapse). Effectiveness was assumed as the percentage of patients with complete
response at the end of the follow-up period using the Hamilton Anxiety Rating Scale 
(HAM-A) (50% reduction related to baseline score) and a Clinical Global Impression
of Improvement (CGI-I) score of 1 or 2. Transition probabilities were obtained
from a meta-analysis involving international published trials. Comparators used in 
the assessment were paroxetine (10–40 mg/day); venlafaxine (75–225 mg/day) and 
pregabalin (300–450 mg/day). Resource use and costs were obtained from 4,000 
randomized hospital records from the Social Security Mexican Institute (IMSS). 
Costs included outpatient and inpatient services, drug, procedures, etc. The model
was calibrated. Probabilistic sensitivity analyses were performed employing boots-
trapping techniques and acceptability curves were constructed. RESULTS: The 
highest percentage of patients with complete response to the HAM-A scale during 
the follow-up period was obtained by pregabalin (39.8%; CI95% 38.5%–41.1%), 
followed by venlafaxine (22.6%; CI95% 21.9%–23.4%) and paroxetine (16.5%;
CI95% 16.0%–17.0%). Regarding the CGI-I the highest percentage for complete 
response was for pregabalin (35.3%; CI95% 34.2%–36.5%); followed by venla-
faxine (28.8%; CI95% 27.8%–29.7%) and paroxetine (16.6%; CI95% 16.1%–
17.2%). The annual expected mean costs per patient were US$1,893.1
(US$1,830.7–US$1955.4), US$2001.2(US$1935.3–US$2067.2) and US$955.1(US$923.6–
US$986.5). The ICER for pregabalin vs. paroxetine (baseline) was US$4019.7
(US$3887.3–US$4153.7) for HAM-A and US$5017.9(US$4852.6–US$5183.2) for 
CGI-I. Second-order Monte Carlo sensitivity analyses showed that pregabalin was a
cost-effective therapy (p  0.05). CONCLUSIONS: Pregabalin showed to be a cost-
effective therapy due to its higher efﬁ cacy response in the management of GAD.
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OBJECTIVES: Recognition and understanding of generalized anxiety disorder (GAD) 
have expanded in recent years. GAD is associated with high use of health care 
resources, predominantly primary care, and its economic burden on society is consid-
erable. The objective of this study was to assess the cost-effectiveness of current
treatments for GAD from the payer’s perspective. METHODS: We developed a micro-
simulation model to estimate costs and effectiveness during a time horizon of 12 
weeks. Effectiveness was assumed as the percentage of patients with complete response
at the end of the follow-up period using the Hamilton Anxiety Rating Scale (HAM-A) 
–over 50% reduction related to baseline score- and Quality Adjusted Life Years
